Browse

Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?

Cited 10 time in Web of Science Cited 12 time in Scopus
Authors
Kim, Hee Seung; Park, Noh-Hyun; Chung, Hyun Hoon; Kim, Jae Weon; Song, Yong-Sang; Kang, Soon-Beom
Issue Date
2008-04-30
Publisher
Oxford University Press
Citation
Jpn J Clin Oncol. 2008;38(6):445-450
Keywords
AdultAgedAntineoplastic Combined Chemotherapy Protocols/*therapeutic useCarboplatin/administration & dosageCarcinoma/*drug therapy/secondaryChemotherapy, AdjuvantDisease-Free SurvivalDrug Administration ScheduleFemaleHumansInfusions, IntravenousKaplan-Meiers EstimateMiddle AgedMultivariate AnalysisNeoplasm StagingOvarian Neoplasms/*drug therapy/pathologyPaclitaxel/administration & dosagePredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesSurvival AnalysisTreatment Outcome
Abstract
BACKGROUND: To evaluate the efficacy of three additional cycles of chemotherapy in patients with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after surgery. METHODS: The clinical data of 94 patients with complete response after six cycles of adjuvant paclitaxel/carboplatin after surgery between January 1997 and March 2007 were reviewed retrospectively. Three additional cycles using the same chemotherapy were administered to 57 patients as consolidation chemotherapy (Group 1). Thirty-seven patients without the additional cycles served as controls (Group 2). Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan-Meier method with the log-rank test. The importance of consolidation chemotherapy as a prognostic factor affecting survival was examined using the Cox's proportional hazard analysis. The incidence of chemotherapy-induced hematological toxicities was compared between the two groups using chi-square test. RESULTS: Median DFS and mean OS were not significantly different between the two groups (15 versus 22 months, P = 0.703; 69 versus 73 months, P = 0.891, respectively). Consolidation chemotherapy was not a prognostic factor of survival although optimal debulking surgery and lower value of serum CA-125 levels after six cycles of the chemotherapy were prognostic factors improving DFS (P < 0.01). Grade 3 or 4 leukopenia was more common in patients treated with consolidation chemotherapy than in those not treated (50.9 versus 21.6%, P = 0.004). CONCLUSION: Consolidation chemotherapy using paclitaxel/carboplatin may be inefficient and relatively toxic to advanced-stage epithelial ovarian cancer patients with complete response to six cycles of the same chemotherapy after surgery.
ISSN
1465-3621 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18508785

http://jjco.oxfordjournals.org/cgi/reprint/38/6/445.pdf

https://hdl.handle.net/10371/68043
DOI
https://doi.org/10.1093/jjco/hyn034
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse